Egetis Therapeutics reports Q3 2026 results
The quarterly report references FDA approval of EMCITATE (triatricol) in the United States; the available text is truncated.
Related stories
SenzaGen Swings to Q3 EBIT Profit of SEK 1.1 Million
M impact | EQUITY | Nov 05, 2026, 06:36 AM UTC
Boho Group Q3 Profit After Tax Rises to SEK 4.17 Million
M impact | EQUITY | Nov 05, 2026, 06:36 AM UTC
Fielmann Q3 Net Profit Rises 9% to EUR 58.07 Million
M impact | EQUITY | Nov 05, 2026, 06:36 AM UTC
Better Life Group Reports Third-Quarter Net Loss of NT$9.23 Million
Better Life Group reported third-quarter revenue of NT$344,000 and pretax profit of negative NT$9,232,000, compared with revenue of NT$343,000 and pretax profit of negative NT$9,78
M impact | EQUITY | Nov 05, 2026, 06:35 AM UTC
Süss MicroTec Q3 Net Profit Falls 87% to EUR 1.43 Million
M impact | EQUITY | Nov 05, 2026, 06:35 AM UTC
Gunze to Buy Back Up to 3.17% of Shares
M impact | EQUITY | Nov 05, 2026, 06:35 AM UTC